Develops targeted cancer medicines, including oral therapies, antibody-drug conjugates and radioligand therapies, for people with cancer.
10-K for FY2025, filed Mar 3, 2026We are a biotechnology company committed to the development of first-in-class and best-in-class targeted oncology therapies. Our goal is to…View ↗
We are advancing a pipeline that includes three clinical assets and three preclinical assets. Varegacestat, formerly AL102, is an…View ↗
IM-3050 is a FAP-targeted lutetium-177, Lu-177 or 177Lu, RLT product candidate for the treatment of solid tumors. FAP is a cell surface…View ↗
AbbVie paid Immunome under a collaboration agreement that ended in July 2025.
10-K for FY2025, filed Mar 3, 2026We have not generated any revenue from product sales and do not expect to do so for the foreseeable future. To date, we have generated our…View ↗
No. It lost $212.4M in FY2025.
10-Q for Q3 FY2026, filed Nov 9, 2026
−$85.8MView ↗
8-K, filed Oct 5, 2026
As consideration for the Amendment, the Company paid BMS $20.0 million in cash and issued 4,425,487 shares of the Company’s common stock…View ↗
From antibody discovery to targeted cancer therapies
The older report describes a memory B-cell platform for discovering antibody treatments, including an infectious-disease program. The latest report centers on targeted oncology therapies, with antibody-drug conjugates and other cancer drug candidates.
10-K for FY2022, filed Mar 16, 2023 10-K for FY2025, filed Mar 3, 2026
Competes with Merck and CStone Pharmaceuticals
10-K for FY2025, filed Mar 3, 2026High or moderate expression of ROR1 has been demonstrated in a variety of hematopoietic malignancies, particularly in B-cell lymphomas, and…View ↗
Loading...